Cargando…

Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma

Glioblastoma (GBM) is the most aggressive brain tumor, with a median survival of ~15 months. Targeted approaches have not been successful in this tumor type due to the large extent of intratumor heterogeneity. Mosaic amplification of oncogenes suggests that multiple genetically distinct clones are p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walentynowicz, Kacper A., Engelhardt, Dalit, Cristea, Simona, Yadav, Shreya, Onubogu, Ugoma, Salatino, Roberto, Maerken, Melanie, Vincentelli, Cristina, Jhaveri, Aashna, Geisberg, Jacob, McDonald, Thomas O., Michor, Franziska, Janiszewska, Michalina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114292/ https://www.ncbi.nlm.nih.gov/pubmed/36920905 http://dx.doi.org/10.1016/j.celrep.2023.112235

Ejemplares similares

In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2(+) breast cancer
por: Janiszewska, Michalina, et al.
Publicado: (2015)

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
por: Rihani, Ali, et al.
Publicado: (2015)

Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma
por: Furgason, John M., et al.
Publicado: (2015)

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer
por: Sitthideatphaiboon, Piyada, et al.
Publicado: (2022)

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
por: Liu, Lin L., et al.
Publicado: (2015)

Frequent Amplification of CENPF, GMNN and CDK13 Genes in Hepatocellular Carcinomas
por: Kim, Hye-Eun, et al.
Publicado: (2012)

CDK4 Amplification Predicts Recurrence of Well-Differentiated Liposarcoma of the Abdomen
por: Lee, Sanghoon, et al.
Publicado: (2014)

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling
por: Park, Silvia, et al.
Publicado: (2014)

EGFR Amplification and Glioblastoma Stem-Like Cells
por: Liffers, Katrin, et al.
Publicado: (2015)

Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors
por: Schwermer, Melanie, et al.
Publicado: (2015)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas
por: Grünewald, Inga, et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Defining EGFR amplification status for clinical trial inclusion
por: French, Pim J, et al.
Publicado: (2019)

Uncertainty quantification in the radiogenomics modeling of EGFR amplification in glioblastoma
por: Hu, Leland S., et al.
Publicado: (2021)

Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages
por: Ochocka, Natalia, et al.
Publicado: (2021)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Ge, Jennifer Y., et al.
Publicado: (2020)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

CDK4 Amplification in Esophageal Squamous Cell Carcinoma Associated With Better Patient Outcome
por: Huang, Jie, et al.
Publicado: (2021)

In Search for Reliable Markers of Glioma-Induced Polarization of Microglia
por: Walentynowicz, Kacper A., et al.
Publicado: (2018)

Egfr Amplification Specific Gene Expression in Phyllodes Tumours of the Breast
por: Agelopoulos, Konstantin, et al.
Publicado: (2007)

EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco
por: Senhaji, Nadia, et al.
Publicado: (2017)

Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification
por: Dekanić, Andrea, et al.
Publicado: (2011)

Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Chloroquine alleviates etoposide-induced centrosome amplification by inhibiting CDK2 in adrenocortical tumor cells
por: Chen, T-Y, et al.
Publicado: (2015)

EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Sesboüé, R, et al.
Publicado: (2012)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
por: Li, Yan, et al.
Publicado: (2022)

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
por: Hwangbo, Won, et al.
Publicado: (2013)

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2015)

EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status
por: Dhawan, Andrew, et al.
Publicado: (2023)

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2(+) breast cancer
por: Janiszewska, Michalina, et al.
Publicado: (2021)

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
por: Sharko, Amanda C., et al.
Publicado: (2021)

EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma
por: Martija, Antoni Andreu, et al.
Publicado: (2023)

Recurrent CDK1 overexpression in laryngeal squamous cell carcinoma
por: Bednarek, K., et al.
Publicado: (2016)

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
por: Martinez-Monleon, Angela, et al.
Publicado: (2022)

DNA secondary structures and epigenetic determinants of cancer genome evolution
por: De, Subhajyoti, et al.
Publicado: (2010)

Evolutionary Dynamics of Intratumor Heterogeneity
por: Iwasa, Yoh, et al.
Publicado: (2011)

Correction: Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies
por: Foo, Jasmine, et al.
Publicado: (2009)

Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies
por: Foo, Jasmine, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_c9ep6o5kf1qsrgfr72n1uuu83l